a cancer diagnostic test that measures the effectiveness of chemotherapy as early as a patient’s first treatment, improving patient experience and outcomes.
Breast cancer is the most common form of cancer in Canadian women, accounting for one in four cancer diagnoses. It is also the second leading cause of cancer deaths, after lung cancer. Determining a breast cancer patient’s response to chemotherapy at an early stage of treatment could allow doctors to more quickly determine whether patients would do better with another therapy. Laurentian University’s Dr. Amadeo Parissenti, along with Health Science North Dr. Baoqing Guo, have come up with a test that can do exactly that. It is called a RNA Disruption Assay.
The knowledge generated by this patented assay will improve treatment and outcomes for breast cancer patients around the world.